Kura Oncology, Inc.
KURANasdaq
$10.86
↓ -0.3%Jul 17 close · end-of-day
Price
1Y↑ +70.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$962.3M
Enterprise Value
$391.2M
P/E
—
P/S
13.4
P/B
8.9
EV/EBITDA
—
PEG
—
FCF Yield
-8.8%
Dividend Yield
—
Revenue (TTM)
$71.6M
Net Income (TTM)
-$294.6M
Free Cash Flow (TTM)
-$84.5M
Gross Margin
—
Operating Margin
-443.5%
Net Margin
-411.2%
ROE
-273.1%
ROIC
—
Debt / Equity
0.1
Net Cash
$571.1M
Return 1Y
+64.5%
Company profile
Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.
- CEO
- Troy E. Wilson
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 130
- Headquarters
- California
- Website
- kuraoncology.com
Management & directors
- Leoni MollieChief Medical Officer
- Powl Brian T.Chief Commercial Officer
- Ford KathleenChief Operating Officer
- Bair Teresa BrophyChief Legal Officer
- Wilson Troy EdwardPresident and CEO
- Burrows FrancisChief Scientific Officer
- Doyle Thomas JamesSVP, Finance & Accounting
Roles derived from SEC Form 4 filings.
Earnings
KURA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$18.3M↑ +29.5%
Diluted EPS-$0.83↑ +25.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $53.9M | $67.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | -$139.9M | -$165.8M | -$193.2M | -$303.6M |
| Net income | -$89.6M | -$130.5M | -$135.8M | -$152.6M | -$174.0M | -$278.7M |
| Diluted EPS | -$1.69 | -$1.97 | -$2.03 | -$2.08 | -$2.02 | -$3.18 |
| Operating cash flow | -$69.8M | -$104.6M | -$110.1M | -$124.8M | $134.3M | -$64.1M |
| Free cash flow | -$72.0M | -$105.7M | -$110.7M | -$125.0M | $133.8M | -$70.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -358.5% | -449.9% |
| Net margin | — | — | — | — | -322.9% | -412.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $14.1M | $15.3M | $20.8M | $17.3M | $18.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$56.4M | -$59.9M | -$22.5M | -$64.7M | -$72.7M | -$80.0M | -$86.3M | -$78.8M |
| Net income | -$50.8M | -$54.4M | -$19.2M | -$57.4M | -$66.1M | -$74.1M | -$81.0M | -$73.3M |
| Diluted EPS | -$0.59 | -$0.63 | -$0.21 | -$0.66 | -$0.75 | -$0.85 | -$0.92 | -$0.83 |
| Operating cash flow | -$42.5M | -$43.4M | $269.1M | -$71.9M | -$28.8M | -$80.6M | $117.3M | -$85.9M |
| Free cash flow | -$42.5M | -$43.4M | $268.8M | -$72.2M | -$30.2M | -$83.2M | $115.0M | -$86.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | -458.6% | -475.3% | -385.5% | -497.6% | -431.5% |
| Net margin | — | — | — | -407.1% | -432.5% | -357.2% | -467.2% | -401.5% |
Company news
Jul 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | Leoni Mollie· Chief Medical Officer | Sale | 84,929 | $9.82 | $834,283.05 | filing |
| 2026-05-21 | Powl Brian T.· Chief Commercial Officer | Sale | 10,000 | $11.00 | $110,000.00 | filing |
| 2026-05-19 | FORD KATHLEEN· Chief Operating Officer | Sale | 2,257 | $9.08 | $20,482.73 | filing |
| 2026-05-19 | Powl Brian T.· Chief Commercial Officer | Sale | 339 | $9.21 | $3,122.19 | filing |
| 2026-05-18 | Bair Teresa Brophy· Chief Legal Officer | Sale | 2,256 | $9.38 | $21,160.15 | filing |
| 2026-03-23 | WILSON TROY EDWARD· President and CEO | Option exercise | 6,103 | $6.15 | $37,533.45 | filing |
| 2026-03-18 | Malley Thomas | Option exercise | 10,000 | $3.12 | $31,200.00 | filing |
| 2026-01-27 | Powl Brian T.· Chief Commercial Officer | Sale | 4,842 | $8.46 | $40,966.23 | filing |
| 2026-01-27 | Bair Teresa Brophy· Chief Legal Officer | Sale | 4,777 | $8.46 | $40,416.76 | filing |
| 2026-01-27 | Bair Teresa Brophy· Chief Legal Officer | Sale | 4,096 | $8.46 | $34,655.03 | filing |
| 2026-01-27 | Leoni Mollie· Chief Medical Officer | Sale | 3,655 | $8.46 | $30,923.86 | filing |
| 2026-01-27 | Bair Teresa Brophy· Chief Legal Officer | Sale | 2,335 | $8.46 | $19,755.73 | filing |
| 2026-01-27 | Leoni Mollie· Chief Medical Officer | Sale | 2,233 | $8.46 | $18,892.74 | filing |
| 2026-01-27 | DOYLE THOMAS JAMES· SVP, Finance & Accounting | Sale | 2,226 | $8.46 | $18,833.52 | filing |
| 2026-01-27 | DOYLE THOMAS JAMES· SVP, Finance & Accounting | Sale | 2,226 | $8.46 | $18,833.52 | filing |
| 2026-01-27 | FORD KATHLEEN· Chief Operating Officer | Sale | 1,813 | $8.46 | $15,339.25 | filing |
| 2026-01-27 | Powl Brian T.· Chief Commercial Officer | Sale | 1,572 | $8.46 | $13,300.22 | filing |
| 2026-01-27 | Leoni Mollie· Chief Medical Officer | Sale | 1,341 | $8.46 | $11,345.80 | filing |
| 2026-01-27 | Burrows Francis· Chief Scientific Officer | Sale | 1,311 | $8.46 | $11,091.98 | filing |
| 2026-01-27 | DOYLE THOMAS JAMES· SVP, Finance & Accounting | Sale | 1,114 | $8.46 | $9,425.22 | filing |
| 2026-01-27 | Leoni Mollie· Chief Medical Officer | Sale | 951 | $8.46 | $8,046.13 | filing |
| 2026-01-27 | DOYLE THOMAS JAMES· SVP, Finance & Accounting | Sale | 881 | $8.46 | $7,453.88 | filing |
| 2026-01-27 | DOYLE THOMAS JAMES· SVP, Finance & Accounting | Sale | 695 | $8.46 | $5,880.19 | filing |
| 2026-01-02 | Leoni Mollie· Chief Medical Officer | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | DOYLE THOMAS JAMES· SVP, Finance & Accounting | Award | 21,250 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.